FOR US HEALTHCARE PROFESSIONALS ONLY
Important Safety Information
Prescribing Information
Find an Injection Center
Request Samples
Access and Support Resources
Important Safety Information
Prescribing Information
Find an Injection Center
Request Samples
Access and Support Resources
Find an Injection Center
Request Samples
Access and Support Resources
Find an Injection Center
Request Samples
Access and Support Resources
Sitemap
INVEGA SUSTENNA
®
Efficacy
Pivotal Studies
Comparative Efficacy Study
Recently Diagnosed Study
Hospital Readmissions Analysis
Safety & Tolerability
Adverse Reactions
Weight Change Data
Extrapyramidal Symptoms Data
Lipids Data
Prolactin Data
Dosing
Initiation and Maintenance
Transitioning from Other Antipsychotics
Missed Doses and Special Populations
Administration
INVEGA SUSTENNA
®
Patient/Caregiver Site
Schizoaffective Disorder
Efficacy
Safety & Tolerability
Dosing
INVEGA TRINZA
®
Efficacy
Long-Term Maintenance Study
Noninferiority Study
Remission Study
Safety & Tolerability
Overall Safety
Metabolic Data
Extrapyramidal Symptoms Data
Prolactin Data
Dosing
Treatment Transition
Missed Doses
Use in Special Populations
Administration
INVEGA TRINZA
®
Patient/Caregiver Site
INVEGA HAFYERA
®
Efficacy
Safety & Tolerability
Overall Safety
Metabolic Data
Extrapyramidal Symptoms Data
Prolactin Data
Dosing
Treatment Transition
Missed Doses
Administration
INVEGA HAFYERA
®
Patient/Caregiver Site
Important Safety Information
INVEGA SUSTENNA
®
, INVEGA TRINZA
®
, INVEGA HAFYERA
®
Important Safety Information
INVEGA SUSTENNA
®
for Schizoaffective Disorder Important Safety Information
RISPERDAL CONSTA
®
(risperidone) Important Safety Information
RISPERDAL
®
(risperidone) Important Safety Information
INVEGA
®
(paliperidone) Important Safety Information
Find an Injection Center
Request Samples
Access and Support Resources
Treatment Conversation Videos
Role of Pharmacists
Considerations for Earlier Use
Treatment Guidelines
LAI Offer & Acceptance
Addressing Patient Concerns
Dosing & Administration
Transition Pathways
Access and Affordability
Back to Top